Financial News Feed

Stronger Sell Today URGN ranks #4995 as SELL CANDIDATE. Weaker Sell
Today URGN ranks #4995 as SELL CANDIDATE.

URGN stock UroGen Pharma Ltd

URGN stock
UroGen Pharma Ltd

Shares of Urogen Pharma Ltd Ordinary Shares (URGN) recently touched 37.225, which places the stock below the Ichimoku cloud, indicating bearish momentum and a potential sell signal for the equity. Sha...

Read more

Doing the necessary homework, investors have a wealth of information about publically traded stocks. Figuring out which ones are going to steadily outperform can be a tricky task. Many investors opt t...

Read more

Shareholder yield has gained increased attention in recent months as a key valuation metric. The measure compares the cash flow a firm is “returning to shareholders” to a stock’s market value. S...

Read more

Wall street brokerage firm analysts are offering a consensus “Buy” rating on shares of UroGen Pharma Ltd. (:URGN). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell an...

Read more

UROGEN PHARMA (:URGN) making news as their share price hit $36.82 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’s trading range is a...

Read more

Urogen Pharma Ltd (NASDAQ:URGN) insider Mark Schoenberg acquired 272 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The stock was acquired at an average cost of $...

Read more

Investors might be taking a closer look into the crystal ball to try and decipher what is in store for the second half of the year in the stock market. While cautious optimism may be the prevailing se...

Read more

Urogen Pharma Ltd Ordinary Shares (URGN) placed on investor’s radar this week as the lagging Chikou 26 day line has dropped below Ichimoku’s Tenkan line, creating an environment ripe for a reversa...

Read more

Here we will take a look at several key ratios for Liberty TripAdvisor Holdings, Inc. (NasdaqGS:LTRP.A), starting with the Book to Market (BTM) ratio. Value investors seek stocks with high BTMs for th...

Read more

Sell-side analysts are expecting EPS growth of 22.70% for UroGen Pharma Ltd. (:URGN) for the year. Analysts are expecting an EPS change of -124.10% for the current year. Wall Street analysts polled by...

Read more

UBS Oconnor LLC lowered its holdings in Urogen Pharma Ltd (NASDAQ:URGN) by 28.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The...

Read more

Urogen Pharma Ltd (NASDAQ:URGN) insider Mark Schoenberg bought 272 shares of Urogen Pharma stock in a transaction dated Thursday, March 21st. The shares were acquired at an average cost of $37.01 per ...

Read more

Even though short-term trading can be very profitable, it can also be a huge risk. Short-term lasts from anywhere from a few minutes or several days or weeks. Traders have to truly understand the risk...

Read more

UROGEN PHARMA (:URGN) has been in the news after the price of the stock hit $36.82 at the conclusion of the most recent close. The stock is traded on NSDQ in the Medical sector and Medical – Biomedi...

Read more

Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) had a decrease of 0.58% in short interest. URGN’s SI was 1.03 million shares in March as released by FINRA. Its down 0.58% from 1.03 million shar...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank